Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 08 - 02 tags : Phase 3 save search
Moderna Announces First Participant Dosed in Phase 1 Study of Its IL-2 mRNA Therapeutic
Published: 2021-08-02 (Crawled : 13:00) - biospace.com/
MRNA | News S | $108.82 0.86% 0.85% 3.4M
|
Health Technology
|
| O: 3.82%
H: 1.56%
C: -3.72%
phase 1 phase 2 phase 3
FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study
Published: 2021-08-02 (Crawled : 12:00) - prnewswire.com
GLMD | $0.3852 6.59% 6.18% 52K
|
Health Technology
|
| O: 7.6%
H: 27.14%
C: 8.55%
fda phase 3 aramchol
Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
Published: 2021-08-02 (Crawled : 12:00) - globenewswire.com
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: 0.21%
H: 2.76%
C: 1.42%
multiple sclerosis sclerosis phase 3
Cytokinetics Announces Start of COURAGE-ALS, a Phase 3 Clinical Trial of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis
Published: 2021-08-02 (Crawled : 12:00) - globenewswire.com
CYTK | $66.76 1.82% 1.78% 810K
|
Health Technology
|
| O: 2.52%
H: 1.57%
C: -3.03%
sclerosis phase 3 trial als
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.